Skip to main content
LymeCare Alliance Logo
Send Your Case

A Case of Persistent Lyme Disease and Neuroborreliosis in Germany: Diagnostic and Treatment Challenges

Share on LinkedIn Facebook

Published on:

Brief Presentation

O.W., a female patient from Germany, has endured a prolonged and complex journey through the healthcare system since her initial Lyme disease symptoms in 2007. After being diagnosed and initially treated with doxycycline, she appeared to recover but began to experience recurring and progressively worsening symptoms over the following years. Her symptoms included eye disturbances, joint pain, neck stiffness, and eventually neurological symptoms, which worsened despite multiple consultations with German healthcare providers. The repeated reliance on the ELISA test, which returned negative results each time, delayed a definitive diagnosis. Finally, after further evaluation by a specialist in the USA in 2016, neuroborreliosis was suspected based on clinical symptoms, and a six-week course of ceftriaxone brought significant improvement. Unfortunately, the disease re-emerged three months after treatment ceased, leading O.W. through years of additional consultations, incorrect diagnoses, and repeated mismanagement.

In 2019, advanced diagnostic testing at a specialized laboratory in Berlin confirmed a persistent infection with Borrelia afzelii, a European strain of Borrelia, through VLsE and line blot tests. Despite these positive results, treatment was refused by a Berlin clinic on the grounds that the tests had been conducted elsewhere. Since 2020, O.W. has received intermittent antibiotic therapy from a Lyme disease specialist, which has helped her manage her symptoms to some extent but has not led to a full recovery.

Conclusion

O.W.’s case highlights the critical limitations of Lyme disease diagnostics and treatment protocols in Germany. Her journey reveals the pitfalls of relying solely on the ELISA test, which is insufficient for detecting chronic and European-specific Borrelia infections, and the lack of acceptance of advanced diagnostic results from outside institutions. This case emphasizes the need for a more comprehensive and integrated approach to Lyme disease, including the acceptance of external diagnostics, the recognition of neuroborreliosis, and the provision of long-term treatment options for chronic cases.

Medical History

  • Initial Lyme Disease Diagnosis (2007): O.W. developed initial symptoms of Lyme disease, which was treated with doxycycline. Following treatment, her symptoms resolved temporarily, and she appeared healthy.
  • Recurrence of Symptoms (2008-2016): In 2008, O.W. began experiencing eye symptoms that were dismissed by German healthcare providers. From 2008 to 2016, her symptoms progressively worsened, affecting her large joints, neck, and spine. Diagnoses ranged from joint overload and psychosomatic disorders to suspected rheumatism, all of which were eventually ruled out. Standard ELISA tests for Lyme disease were repeatedly performed but consistently returned negative results, delaying further diagnostic considerations.
  • Clinical Suspicion of Neuroborreliosis (2016): After suffering from neck stiffness and involuntary curling of her thumbs, O.W. consulted an infectious disease specialist in the USA, who suspected neuroborreliosis based on clinical symptoms. The specialist initiated a six-week course of ceftriaxone, leading to a temporary but significant improvement in her condition. However, the disease symptoms gradually returned three months after completing treatment.
  • Confirmation of Borrelia Infection (2019): After years of incorrect diagnoses, O.W. finally underwent comprehensive diagnostic testing in 2019 at a specialized laboratory in Berlin. Advanced methods, including VLsE and line blot testing, confirmed the presence of Borrelia afzelii, a European strain of Borrelia. The VLsE result was borderline, but the line blot IgG and IgM antibodies were clearly positive, indicating a persistent Borrelia infection.

Symptoms

  • Ocular Symptoms: In 2008, O.W. experienced eye disturbances, which were initially dismissed by German doctors.
  • Joint Pain and Inflammation: Progressive pain and dysfunction in large joints, along with issues in the neck and spine, were noted between 2008 and 2016. These symptoms were frequently attributed to joint overload or suspected rheumatism, despite a lack of confirmatory evidence.
  • Neurological Symptoms: In 2016, O.W. developed a stiff neck, muscle spasms, and spontaneous curling of her thumbs, consistent with neurological involvement and neuroborreliosis.
  • Fluctuating Symptoms: Since 2020, O.W. has managed intermittent symptoms with antibiotic therapy, but her condition remains unstable and she continues to experience joint and neurological symptoms.

Diagnostic Tests

  1. ELISA Tests (Germany, 2007-2016): Repeated ELISA tests were performed during O.W.’s initial diagnostic journey, but each test returned negative results. The ELISA test is known for its limitations in detecting chronic Lyme disease and European strains, which likely contributed to the repeated false-negative outcomes.
  2. Clinical Diagnosis of Neuroborreliosis (USA, 2016): Based on clinical symptoms, a US infectious disease specialist suspected neuroborreliosis and initiated a six-week course of ceftriaxone. This clinical approach was necessary due to the limitations of standard testing methods in detecting European strains of Borrelia in the USA.
  3. VLsE and Line Blot Tests (Berlin, 2019): Advanced testing conducted at a Berlin laboratory included the VLsE and line blot methods. The VLsE test returned a borderline result, but the line blot IgG and IgM antibodies were positive, confirming a persistent infection with Borrelia afzelii. This strain is common in Europe but often overlooked in standard testing panels.

Diagnosis and Treatment Challenges

Despite conclusive test results from advanced diagnostics in Berlin, German healthcare providers were hesitant to recognize the results. A prominent Berlin clinic refused to initiate treatment, arguing that they could not accept diagnostic results conducted by an external laboratory. The clinic further suggested that the laboratory responsible for the diagnosis should handle the treatment, leading to a delay in care.

O.W. eventually consulted a Lyme disease specialist who began treating her in 2020 with various antibiotic combinations. While this treatment allowed her to manage her symptoms intermittently, it was not a curative approach. The lack of acceptance of the Berlin diagnostic results and the reliance on intermittent antibiotic therapy underscore the challenges faced by patients with persistent and complex Lyme disease in Germany.

Outcomes

  • Improvement with Initial Antibiotic Treatment (2016): The six-week ceftriaxone treatment in 2016 led to a temporary but significant improvement in O.W.’s symptoms, suggesting that her symptoms were indeed related to an ongoing infection.
  • Symptom Recurrence: Three months after completing ceftriaxone, O.W.’s symptoms returned, signaling an incomplete treatment response or a relapse of the infection. The persistence of symptoms highlights the need for more prolonged or targeted therapy in chronic cases.
  • Intermittent Symptom Management (2020-Present): Since 2020, O.W. has managed her condition with periodic antibiotic treatment from a Lyme disease specialist. However, her symptoms remain, and her quality of life has been impacted by the limitations of this approach.

Differential Diagnosis

  • Chronic Lyme Disease and Neuroborreliosis: The confirmed presence of Borrelia afzelii, combined with O.W.’s neurological symptoms and the temporary response to ceftriaxone, strongly suggests chronic Lyme disease with neuroborreliosis.
  • Rheumatologic Conditions: Rheumatologic conditions were considered early in O.W.’s diagnostic journey, given her joint pain and musculoskeletal symptoms. However, testing did not support a diagnosis of rheumatism or other autoimmune disorders.
  • Psychosomatic Disorders: Psychosomatic factors were hypothesized early in O.W.’s diagnostic journey but were ruled out by a psychiatrist. The persistence of physical symptoms and positive serology later confirmed that her condition was not psychosomatic.

Future Recommendations

  • Comprehensive and Extended Antibiotic Therapy: Given the chronic and relapsing nature of O.W.’s infection, she may benefit from an extended, combination antibiotic regimen. Treatment should ideally involve both oral and intravenous antibiotics, tailored to address neuroborreliosis and the persistence of Borrelia afzelii.
  • Regular Monitoring and Follow-Up: Ongoing follow-up with a Lyme disease specialist is essential to monitor O.W.’s response to treatment and adjust therapy as needed. Regular blood tests, including advanced serological tests, should be conducted to track the infection’s activity.
  • Access to Integrated Care: O.W. would benefit from an integrated care approach involving infectious disease specialists, neurologists, and rheumatologists who are familiar with complex Lyme disease presentations. A multidisciplinary team can help address her joint, neurological, and systemic symptoms in a coordinated manner.
  • Advocacy for Acceptance of Modern Diagnostics: This case highlights the need for German healthcare providers to accept results from advanced diagnostic methods, particularly those from reputable laboratories. Training and guidelines should be updated to recognize the validity of VLsE and line blot results, especially for European strains of Borrelia.
  • Long-Term Symptom Management: Since O.W.’s symptoms have persisted for years, a comprehensive symptom management plan should be implemented, including physical therapy, pain management, and psychological support to help her manage the long-term impact of the disease.

Discussion

O.W.'s case highlights the diagnostic and treatment challenges of managing persistent Lyme disease and neuroborreliosis, particularly in Germany, where standard testing methods often fall short. The initial reliance on the ELISA test, despite its limitations for chronic and European-specific Borrelia strains, delayed her diagnosis for years. The ELISA test is known to be less sensitive than other methods, such as Western Blot, VLsE, and line blot, especially for detecting persistent infections or specific European strains. This shortcoming contributed to O.W.’s prolonged suffering and reliance on various inaccurate diagnoses over nearly a decade.

The clinical suspicion of neuroborreliosis by a specialist in the USA underscores the importance of clinical diagnosis in cases where testing methods are insufficient. The temporary improvement following ceftriaxone treatment in 2016 suggested an underlying infection, yet the German healthcare system’s failure to recognize this possibility delayed further treatment. Finally, advanced testing in Berlin in 2019 provided definitive evidence of an ongoing infection with Borrelia afzelii, yet even with clear positive results, her treatment was refused by a German clinic due to the tests’ external origin. This reflects a systemic reluctance to accept diagnostic results from outside institutions, which poses significant barriers to timely and effective care for Lyme disease patients.

Broader Implications

O.W.’s case underscores the critical need for reform in Lyme disease diagnostics and treatment in Germany. The lack of acceptance of advanced diagnostic results from specialized laboratories hinders the diagnosis and treatment of patients with chronic Lyme disease and neuroborreliosis. Her experience highlights the necessity for updated training and guidelines that include more sensitive diagnostic tools and greater recognition of European Borrelia strains.

By implementing these changes, Germany could better support patients with complex Lyme disease presentations, preventing prolonged suffering and unnecessary financial burdens. This case also emphasizes the importance of multidisciplinary care for chronic Lyme patients, ensuring they receive comprehensive treatment that addresses all aspects of the disease, from infection control to symptom management. O.W.’s journey through the healthcare system serves as a call to action for more inclusive, evidence-based protocols that prioritize patient well-being.

This expanded case report provides a detailed analysis of O.W.’s medical journey, highlighting the systemic challenges she faced in obtaining a diagnosis and effective treatment for persistent Lyme disease and neuroborreliosis. It underscores the broader implications of these challenges for the German healthcare system and the need for reform.

Analysis of O.W.’s Case: The Diagnostic and Treatment Challenges of Chronic Lyme Disease and Neuroborreliosis in Germany

O.W., a female patient from Germany, has faced a prolonged struggle to secure a diagnosis and adequate treatment for Lyme disease and suspected neuroborreliosis. Since her initial infection in 2007, she has experienced recurring and worsening symptoms, including eye disturbances, joint pain, and neurological manifestations, which were repeatedly dismissed or misdiagnosed within the German healthcare system. This case underscores the critical need for systemic improvements in diagnostic protocols, treatment acceptance, and the handling of chronic Lyme disease in Germany.

Initial Missteps: Over-Reliance on ELISA Testing

O.W.’s journey began with initial symptoms in 2007, after which she received a short course of doxycycline that provided temporary relief. However, her symptoms returned and worsened over time, developing into a constellation of ocular, joint, and neurological symptoms. Throughout this period, she underwent multiple ELISA tests for Lyme disease, all of which returned negative. The ELISA test is known for its limitations, especially in detecting chronic or European-specific Borrelia infections, such as Borrelia afzelii, which is often implicated in neuroborreliosis and other chronic manifestations in Europe. The repeated reliance on this single test led to numerous missed diagnostic opportunities, ultimately delaying her treatment.

The ELISA test detects antibodies, which may not be present or detectable in chronic cases of Lyme disease, especially as the immune response declines over time. O.W.’s case illustrates the risks associated with using ELISA as a primary diagnostic tool for persistent infections and highlights the need for more sensitive and specific tests, such as Western Blot, VLsE, and line blot assays. The failure to utilize these more effective methods in Germany contributed directly to her diagnostic delays and the progression of her disease.

Clinical Diagnosis and Temporary Relief in the USA

In 2016, after years of worsening symptoms, including muscle spasms and neck stiffness, O.W. sought a second opinion from an infectious disease specialist in the USA. Based on her clinical symptoms, the specialist suspected neuroborreliosis and initiated a six-week course of ceftriaxone. This treatment resulted in a significant but temporary improvement, underscoring the likelihood of an active, ongoing infection. However, her symptoms re-emerged just three months after the treatment ended, signaling either an incomplete response to therapy or a relapse. This transient improvement further supports the presence of neuroborreliosis, yet the German healthcare providers remained reluctant to acknowledge it due to their reliance on ELISA test results.

This part of O.W.’s experience emphasizes the importance of clinical diagnosis in complex Lyme disease cases, particularly when traditional testing methods fall short. The USA specialist’s willingness to rely on clinical evidence to initiate treatment proved beneficial, even if only temporarily. O.W.'s case highlights the necessity for German physicians to consider clinical presentations as part of their diagnostic process, particularly for patients with chronic and neurological Lyme disease.

Confirmation of Borrelia afzelii Infection and Treatment Refusal in Germany

After a decade of incorrect diagnoses and delayed treatment, O.W. finally received confirmation of a persistent Borrelia infection in 2019 through advanced testing conducted at a specialized laboratory in Berlin. The VLsE test returned a borderline result, while the line blot test showed positive IgG and IgM antibodies, indicating an active infection with Borrelia afzelii, a strain common in Europe. This finding provided conclusive evidence of her chronic infection and validated the clinical suspicion of neuroborreliosis. Despite these results, a prominent Berlin clinic refused to initiate treatment, citing the fact that the diagnostics were conducted externally. This refusal to accept advanced diagnostics from reputable laboratories reflects a systemic reluctance within the German healthcare system to incorporate external diagnostic findings, leaving patients like O.W. without appropriate care.

The issue of rejecting external diagnostics poses a significant barrier to timely treatment and exacerbates patient suffering. The need for greater acceptance of reputable diagnostic results from outside institutions is critical for improving patient outcomes. By refusing to acknowledge the results of advanced testing, German healthcare providers are effectively denying patients access to the full range of diagnostics necessary to detect and treat persistent Lyme infections accurately.

The Financial and Emotional Toll of Chronic Lyme Disease

O.W.’s years-long struggle for diagnosis and treatment have not only affected her physical health but also taken an immense financial and emotional toll. Seeking consultations abroad and repeated attempts at diagnosis and treatment have likely led to considerable out-of-pocket expenses, creating a significant financial burden. The emotional impact of being dismissed and misdiagnosed over a period of years compounds the difficulties faced by patients with chronic Lyme disease. The psychological toll of chronic illness, especially when accompanied by diagnostic delays and skepticism from healthcare providers, cannot be overstated. Support structures, including mental health resources and patient advocacy, are essential components of a comprehensive care plan for chronic Lyme patients.

Recommendations for Improved Care

  1. Long-Term Combination Antibiotic Therapy: Given the persistence of O.W.’s symptoms and confirmed Borrelia afzelii infection, she would benefit from a more extensive antibiotic regimen tailored to address neuroborreliosis. Both oral and intravenous antibiotics, administered over a prolonged period, may be required to achieve lasting improvement. Treatment should be closely monitored and adjusted based on her response.

  2. Regular Monitoring with Advanced Diagnostics: Ongoing evaluation using advanced diagnostic methods, such as VLsE, line blot, and Western Blot, would help track the infection’s progression and guide adjustments in therapy. Monitoring should include blood work and clinical evaluations to assess both infection levels and immune response.

  3. Integrated Multidisciplinary Approach: Due to the multisystemic nature of her symptoms, O.W. would benefit from a coordinated, multidisciplinary approach involving specialists in infectious diseases, neurology, rheumatology, and possibly ophthalmology. This collaborative approach would allow for a more holistic understanding of her condition and enable comprehensive management of her symptoms.

  4. Acceptance of External Diagnostic Results: Germany’s healthcare system would benefit from more flexible policies regarding the acceptance of external diagnostic findings, especially from recognized and specialized laboratories. Providing physicians with guidelines that support the acceptance of advanced tests, such as line blot and VLsE, would prevent further delays in treatment and improve patient outcomes.

  5. Symptom Management and Psychological Support: For long-term symptom relief, a comprehensive management plan that includes physical therapy, pain management, and psychological support is essential. Addressing the emotional impact of her prolonged illness and mismanagement through counseling or support groups would help O.W. manage the mental health challenges associated with chronic Lyme disease.

Broader Implications for Lyme Disease Care in Germany

O.W.’s experience highlights systemic issues within Germany’s approach to Lyme disease and neuroborreliosis. The reliance on ELISA testing, despite its known limitations in detecting chronic infections, illustrates the need for updated protocols that prioritize more sensitive tests for patients presenting with complex, relapsing symptoms. Additionally, the refusal to acknowledge external diagnostic findings hinders the timely initiation of treatment and denies patients the full range of available diagnostics. Adopting international diagnostic standards, particularly for European strains of Borrelia, would enable German healthcare providers to provide more accurate and effective care.

The financial and emotional toll of prolonged misdiagnosis and mistreatment, as experienced by O.W., reflects a broader need for more accessible diagnostic options and patient advocacy in Germany. To prevent other patients from facing similar challenges, Germany must update its training, guidelines, and acceptance criteria for Lyme disease diagnostics, especially for chronic and complex cases.

Conclusion: A Call for Diagnostic Reform and Comprehensive Care

O.W.’s case exemplifies the serious consequences of relying on outdated diagnostics and dismissing advanced diagnostic findings for chronic Lyme disease. Her journey highlights the limitations of the ELISA test and the critical need for more comprehensive diagnostic tools, especially those that address European strains of Borrelia. The German healthcare system’s failure to accept her Berlin laboratory results underscores the systemic barriers Lyme disease patients face in securing appropriate treatment.

To prevent cases like O.W.’s, the German healthcare system must reform its approach to chronic Lyme disease, incorporating a more evidence-based and patient-centered model. This includes updating diagnostic protocols to include sensitive testing options, providing training to recognize chronic Lyme and neuroborreliosis, and ensuring that healthcare providers are open to credible external diagnostic results. Only through such reforms can Germany hope to address the growing burden of chronic Lyme disease and prevent unnecessary suffering and disability among its patients.

Latest Case Studies

Latest publications